Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329589 · ClinicalTrials.gov registry record · Phase 1
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00329589 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 54 participants.
The verdict
NCT00329589, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of Velcade when used with chemoradiation in cancer patients.
Interventions
- DRUG Velcade (bortezomib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329589
The ClinicalTrials.gov registry entry for NCT00329589 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Velcade (bortezomib) is the first listed.
NCT00329589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329589 about?
NCT00329589 is a clinical study titled "A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients". The purpose of this study is to determine the safety of Velcade when used with chemoradiation in cancer patients.
What is the current status of trial NCT00329589?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2005-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00329589?
The interventions under investigation include: Velcade (bortezomib) (DRUG).
Who is sponsoring clinical trial NCT00329589?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.